Simdax Iv Infusion Icin Konsantre Solution Iceren Vial

Description

Active Ingredient

Levosimendan: Each ml of concentrate contains 2.5 mg of levosimendan. Available in vials containing either 12.5 mg (5 ml) or 25 mg (10 ml) of levosimendan.

Excipients

A detailed list of excipients can be found in the product documentation.

Pharmaceutical Form Simdax is supplied as a clear yellow or orange solution concentrate for infusion, which must be diluted prior to administration.

Therapeutic Indications Simdax is indicated for short-term treatment of acutely decompensated severe chronic heart failure (ADHF) when conventional therapy is insufficient and inotropic support is needed.

Dosage and Administration

Method of Administration

Simdax must be diluted before use and can be administered via peripheral or central venous routes. It is intended for intravenous use only.

Dosage

Loading Dose

• Initial Dose: 6-12 micrograms/kg infused over 10 minutes.
• Lower Dose: 6 micrograms/kg for patients receiving other intravenous vasodilators or inotropes.

Continuous Infusion

• Standard Rate: 0.1 micrograms/kg/min.
• Adjustments: Increase to 0.2 micrograms/kg/min if stronger haemodynamic effect is needed or decrease to 0.05 micrograms/kg/min if adverse effects like hypotension or tachycardia occur.

Duration

• Infusion Duration: Recommended duration is 24 hours.
• Monitoring: Patients should be monitored during treatment and for at least three days post-infusion or until clinically stable.

Clinical Effects

Haemodynamic and Neurohormonal Effects

• Decreased pulmonary capillary wedge pressure
• Increased cardiac output (index)
• Increased stroke volume
• Decreased systemic vascular resistance
• Decreased pulmonary vascular resistance
• Reduced natriuretic peptide levels

Other Clinical Effects

• Symptom relief for heart failure
• Effects sustained with beta-blockers
• Prolonged effects due to active metabolite
• No development of tolerance
• No increase in myocardial oxygen consumption
• Anti-ischemic effect
• No impairment of diastolic function

Safety and Monitoring

Monitoring Patients should be monitored during treatment, including urine output measurements, for at least three days post-infusion or until clinically stable.

Special Populations

• Renal Impairment: Use with caution in mild to moderate cases; avoid in severe impairment.
• Hepatic Impairment: Use with caution in mild to moderate cases; avoid in severe impairment.
• Children: Not recommended for patients under 18 years of age.

Common Side Effects of Simdax

Very Common (may affect more than 1 in 10 people)

• Abnormally fast heartbeat (tachycardia)
• Headache
• Drop in blood pressure (hypotension)

Common (may affect up to 1 in 10 people)

• Dizziness
• Ventricular tachycardia
• Extrasystoles (extra heartbeats)
• Atrial fibrillation (AF)
• Hypokalaemia (low potassium levels)
• Insomnia
• Gastrointestinal disturbances
• Anaemia

Potentially Fatal

• Arrhythmias
• Tachycardia
• Atrial fibrillation with rapid ventricular response

If these side effects occur, contact a healthcare professional immediately.

Comparison with Other Heart Failure Medications

Mechanism of Action

Simdax (Levosimendan)

• Inotropic and vasodilatory effects: Enhances cardiac contractility through calcium sensitization and promotes vasodilation by opening ATP-dependent potassium channels on vascular smooth muscle cells.
• Sustained Effects: Active metabolite provides sustained haemodynamic effects for up to two weeks.

Dobutamine

• Inotropic Agent: Increases cardiac output by stimulating beta-1 adrenergic receptors, leading to increased heart rate and contractility.
• Short Duration: Effects are short-lived, requiring continuous infusion.

Milrinone

• Phosphodiesterase Inhibitor: Increases cardiac output by inhibiting phosphodiesterase-3, leading to increased intracellular cyclic AMP and calcium levels.
• Vasodilatory Effects: Reduces preload and afterload, similar to Levosimendan.

Clinical Effects

Simdax (Levosimendan)

• Haemodynamic Stability: Provides significant benefits without increasing myocardial oxygen consumption.
• Beta-Blocker Compatibility: Effects maintained with concurrent beta-blocker use.
• Extended Benefits: Effects persist for 7-10 days post-infusion.

Dobutamine

• Rapid Onset: Quick relief of heart failure symptoms.
• Tolerance Development: Potential for tolerance with prolonged use.

Milrinone

• Effective in Severe Cases: Used in severe heart failure and cardiogenic shock.
• Hypotension Risk: Requires careful monitoring due to the risk of hypotension.

Safety and Monitoring

Simdax (Levosimendan)

• Monitoring Required: Essential during treatment and for at least three days post-infusion.
• Renal and Hepatic Impairment: Use with caution in mild to moderate impairment.

Dobutamine

Continuous Monitoring: Needed due to the risk of arrhythmias and increased myocardial oxygen consumption.

Milrinone

Invasive Monitoring: Often necessary due to the risk of hypotension and arrhythmias.

Contraindications for Simdax

Hypersensitivity

Patients with known hypersensitivity to Levosimendan or any excipients should avoid Simdax.

Cardiovascular Conditions

• Severe hypotension
• Severe tachycardia
• Significant mechanical obstructions (e.g., aortic stenosis, mitral stenosis, LVOT obstruction)
• History of Torsade de Pointes

Renal and Hepatic Impairment

• Severe renal impairment (creatinine clearance <30 mL/min)
• Severe hepatic impairment

Other Considerations

Not for use in children and adolescents under 18 years of age.

Potential Drug Interactions with Simdax

Increased Risk of Hypotension

• IV Vasoactive Drugs: Concomitant use can increase hypotension risk.
• Isosorbide Mononitrate: Can significantly potentiate orthostatic hypotensive response.

No Significant Interactions

• Warfarin: Levosimendan does not inhibit CYP3A or CYP2C9; metabolism unaffected by CYP3A inhibitors.
• Felodipine and Itraconazole: No significant interactions observed.

General Considerations

Other Inotropic Agents: Limited experience with concomitant use, except digoxin.

Pharmacokinetics

Absorption

Administered intravenously, bypassing the typical absorption phase of oral drugs.

Distribution

• Volume of Distribution (Vss): Approximately 0.2 L/kg.
• Protein Binding: 97-98% bound to plasma proteins, primarily albumin. Active metabolites (OR-1855 and OR-1896) have mean protein binding values of 39% and 42%, respectively.

Metabolism

• Primarily metabolized by conjugation to cyclic or N-acetylated cysteinylglycine and cysteine conjugates.
• About 5% metabolized in the intestine to aminophenylpyridazinone (OR-1855), reabsorbed and further metabolized to active metabolite OR-1896.

Excretion

• Renal Excretion: 95% conjugated with glutathione to inert cysteine and renally excreted.
• Half-Life: Approximately one hour, but active metabolites have longer half-lives, contributing to prolonged effects.

Administration in Clinical Practice

Preparation

Simdax must be diluted before use. Typical dilution: 5 ml Simdax concentrate into 250 ml 5% glucose solution, resulting in 0.05 mg/ml concentration.

Method of Administration

• For intravenous use only, can be administered peripherally or centrally.
• Loading Dose: 6-12 micrograms/kg infused over 10 minutes.
• Continuous Infusion: 0.1 micrograms/kg/min. Dose and duration should be individualized based on clinical response.

Monitoring

• Continuous monitoring of patients during treatment, including urine output. Monitoring should continue for at least three days post-infusion or until clinically stable.

Special Considerations

• Adjustments: Lower loading doses for patients on other intravenous vasodilators or inotropes.
• Response Assessment: Adjust infusion rate based on clinical response to avoid excessive effects like hypotension or tachycardia.

Table: Key Information on Simdax (Levosimendan)

Aspect	Details
Usage	Short-term treatment of acutely decompensated severe chronic heart failure
**	Dosage
Benefits	Significant haemodynamic and neurohormonal effects Symptom relief in heart failure Effects maintained with beta-blockers Sustained benefits due to active metabolites
Common Side Effects	Tachycardia, headache, hypotension, dizziness, ventricular tachycardia, atrial fibrillation, hypokalaemia, insomnia, gastrointestinal disturbances, anaemia
Potentially Fatal Side Effects	Arrhythmias, rapid tachycardia, atrial fibrillation with rapid ventricular response
Contraindications	Hypersensitivity to Levosimendan or excipients Severe hypotension Severe tachycardia Significant mechanical obstructions History of Torsade de Pointes Severe renal or hepatic impairment Not for children and adolescents under 18 years
Drug Interactions	Increased risk of hypotension with IV vasoactive drugs and isosorbide mononitrate No significant interactions with Warfarin, Felodipine, or Itraconazole
Pharmacokinetics	Absorption: Intravenous administration Distribution: 0.2 L/kg volume of distribution, 97-98% protein-bound Metabolism: Primarily conjugated, with active metabolites Excretion: Renal, 95% excreted, half-life approximately 1 hour for Levosimendan (longer for metabolites)
Monitoring	Continuous monitoring during and for at least three days post-infusion Monitoring of urine output

Conclusion

Simdax (Levosimendan) offers substantial benefits in the short-term management of acutely decompensated severe chronic heart failure. It combines inotropic and vasodilatory effects, providing haemodynamic stability and symptom relief without increasing myocardial oxygen consumption. The drug’s compatibility with beta-blockers and prolonged haemodynamic effects make it a valuable therapeutic option. However, its administration requires careful monitoring, particularly in patients with renal or hepatic impairment, to ensure safety and efficacy.